Heart rhythm risks in ATTR amyloidosis patients on tafamidis under scrutiny
NCT ID NCT06251778
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study follows 200 adults with ATTRwt amyloidosis who are taking tafamidis to see how often they develop heart rhythm problems that need a pacemaker or defibrillator. Researchers will also track changes in diuretic use. Participants are checked every six months as part of routine care.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- tafamidis
- What this could lead to
- If successful, this study could improve how doctors monitor and manage heart rhythm problems in people with ATTR amyloidosis.
- What could go wrong
- This is an observational study, not a treatment trial. It may not lead to new therapies, and results depend on routine care, which varies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AMYLOIDOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fondazione IRCCS Policlinico San Matteo
RECRUITINGPavia, 27100, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A hidden warning in your wrist? surgery may reveal heart risk
- A carpal tunnel clue to a silent heart threat?
- Can a daily pill keep a rare heart disease in check for the long haul?
- Hidden heart condition may affect aortic stenosis outcomes – can imaging catch it?
- Heart drug acoramidis tested for Long-Term cardiac repair in rare amyloidosis
- Heart imaging may reveal hidden clues in rare heart disease